# Clinical Trials Data EGFR - Document 43

# A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01858389

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Evidence of histologically confirmed, advanced NSCLC (stage IIIB/IV).\n\* Evidence of T790M mutation to enroll in Cohort A.\n\* Evidence of measurable disease by radiographic technique.\n\* Adequate organ function.\n\nExclusion Criteria:\n\n\* Patients with T790M mutation who stopped any prior EGFR-directed therapy without evidence of disease progression.\n\* Symptomatic brain metastases.\n\* Uncontrolled or significant cardiovascular disease.\n\* Pregnant or breastfeeding.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial requires evidence of a \*\*T790M mutation\*\*, not just any EGFR mutation. Therefore, a patient with a general EGFR mutation but \*without\* the T790M mutation would \*not\* be eligible for this particular trial. They would only be eligible if they specifically had the T790M mutation in addition to their other EGFR mutation.